• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

Guidance for Industry: ANDAs: Stability Testing of Drug Substances and Products

PDF Printer Version

CDER Logo

 

DRAFT GUIDANCE
 
            This guidance document is being distributed for comment purposes only.
 
Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register.
 
For questions regarding this draft document contact (CDER) Radhika Rajagopalan 240-276-8546. 
  
 
U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
 
September 2012
OGD
  
Guidance for Industry
ANDAs: Stability Testing of Drug Substances and Products
 
 
Additional copies are available from:
Office of Communications
Division of Drug Information, WO51, Room 2201
Center for Drug Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave., Silver Spring, MD 20993
Phone: 301-796-3400; Fax: 301-847-8714
 
U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
September 2012
OGD
  
TABLE OF CONTENTS
  
 
I.        INTRODUCTION
II.       BACKGROUND
III.      DISCUSSION 


 

Guidance for Industry[1]
ANDAs: Stability Testing of Drug Substances and Products
 
 
 
 
I.          INTRODUCTION
 
This guidance recommends that abbreviated new drug applications (ANDAs) submitted pursuant to section 505(j) of the Federal Food, Drug and Cosmetic Act, and the drug master files (DMFs) that support ANDAs, follow the stability recommendations provided in International Conference on Harmonisation (ICH) stability guidances.    
 
FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.
 
II.        BACKGROUND
 
Over the past few years, the Office of Generic Drugs (OGD) has been receiving numerous inquiries about stability data requirements for ANDAs. Current published guidance from OGD consists of a 1995 industry letter which states OGD will accept ICH recommended long-term room temperature conditions for stability studies (i.e., 25±2°C, 60±5% RH). Although adequate in the context of other guidance existing at that time, this recommendation is no longer sufficient to serve as a basis for stability testing for ANDAs. 
 
The following existing ICH guidances address stability for new drug substances and products:
 
1.     Q1A (R2) Stability Testing of New Drug Substances and Products.
 
2.     Q1B Photostability Testing of New Drug Substances and Products.
 
3.     Q1C Stability Testing for New Dosage Forms.
 
4.     Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products.
 
5.     Q1E Evaluation of Stability Data  [2]
 
These will be referred to in the discussion that follows as ICH stability guidances. 
 
III.          DISCUSSION
 
Although the ICH stability guidances were developed by ICH to provide guidance on the information that should be provided in new drug applications to ensure the stability of new drug substances and drug products, we believe the recommendations should be applied to ANDAs as well.
 
When following the ICH stability recommendations, the applicant should:
 
1.      Submit data from three pilot scale batches or two pilot batches and one small scale batch. If the size of the pilot does not follow ICH recommendations, the applicant should provide a justification.
 
2.      At the time of submission, provide 6 months of data that include accelerated and long-term conditions. FDA recommends following ICH with respect to utilization of intermediate conditions to support shelf-life.
 
3.      Use multiple lots of drug substance as appropriate.
 
4.      Manufacture and package the drug product using principles that are representative of the commercial process.
 
5.      Provide a fully packaged primary exhibit batch.
 
6.      Use three batches when using bracketing and matrixing designs under ICH Q1D.
 
7.      Provide statistical analysis of the data as appropriate, in accordance with ICH Q1E, Appendix A.
 
If you choose to deviate from the above recommendations, you should justify the approach you are taking. 


[1] This guidance has been prepared by the Office of Generic Drugs, Office of Pharmaceutical Science in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration.
[2] We update guidances periodically. To make sure you have the most recent version of a guidance, check the FDA Drugs guidance Web page at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.